Posted by Michael Wonder on 01 Jun 2021
BridgeBio Pharma receives FDA fast track designation for encaleret for the treatment of autosomal dominant hypocalcaemia type 1
1 June 2021 - BridgeBio Pharma today announced that the U.S. FDA granted fast track designation for encaleret for the treatment of autosomal dominant hypocalcaemia.
Autosomal dominant hypocalcaemia type 1 is a rare, genetic form of hypoparathyroidism caused by pathogenic variants in the calcium-sensing receptor gene.
